U 89678

Known as: U-89678 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Biotransformation of tirilazad in human: 3. tirilazad A-ring reduction by human liver microsomal 5alpha-reductase type 1 and type 2.
Tirilazad mesylate (FREEDOX), a potent inhibitor of membrane lipid peroxidation in vitro, is under clinical development for the… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • table 1
Is this relevant?
1998
1998
Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.
The effect of oral finasteride, an inhibitor of 5alpha-reductase, on the clearance of tirilazad, a membrane lipid peroxidation… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
1997
1997
Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults.
The pharmacokinetics of tirilazad and U-89678 (an active metabolite) were evaluated in 55 adults (48 males, 7 females) with… (More)
Is this relevant?
1997
1997
Pharmacokinetics of tirilazad in healthy male subjects at doses above 6 mg/kg/day.
The dose proportionality of tirilazad pharmacokinetics at dosages above 6.0 mg/kg/day were assessed in 18 healthy male volunteers… (More)
Is this relevant?
1996
1996
Protective effects of tirilazad mesylate and metabolite U-89678 against blood-brain barrier damage after subarachnoid hemorrhage and lipid peroxidative neuronal injury.
The 21-aminosteroid lipid-peroxidation inhibitor, tirilazad mesylate (U-74006F), recently was shown in a large multinational… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1996
1996
Gender does not affect the degree of induction of tirilazad clearance by phenobarbital
Objective: Tirilazad mesylate is a membrane lipid peroxidation inhibitor being evaluated for the treatment of patients with… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
1996
1996
Pharmacokinetics of tirilazad and U-89678 in ischemic stroke patients receiving a loading regimen and maintenance regimen of 10 mg/kg/day of tirilazad.
The pharmacokinetics of tirilazad mesylate and its active reduced metabolite, U-89678, were evaluated in ischemic stroke patients… (More)
Is this relevant?
1995
1995
Effect of Gender and Menopausal Status on the Pharmacokinetics of Tirilazad Mesylate in Healthy Subjects.
The pharmacokinetics of tirilazad were assessed in men ages 40--60 years, women <40 years of age, premenopausal women ages 40--60… (More)
Is this relevant?
1994
1994
Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers.
Multiple dose pharmacokinetics and tolerability of tirilazad mesylate were assessed at the maximum dosage and duration expected… (More)
Is this relevant?
1994
1994
The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers.
The pharmacokinetic interaction between phenytoin and tirilazad was studied in 12 healthy men who received 200 mg phenytoin… (More)
Is this relevant?